Target Corporation (TGT) is scheduled to report fourth-quarter 2018 results on Tuesday, March 5, before market open. The Street anticipates earnings will grow over 11% year-over-year to $1.53 per share and revenue will gain by 1.7% to $23.1 billion.
Target is likely to deliver positive fourth-quarter results thanks to a holiday season that turned out pretty well. Last month, the company said its comparable sales for the November/December period grew 5.7%, helped by strong traffic and positive store comps. Comparable sales have grown more than 9% over the past two years.
Comparable digital sales grew 29% in November/December fuelled by store-fulfilled digital sales growth. Target expects digital sales to grow more than 25% for the fifth consecutive year in 2018. Store Pickup plus Drive Up grew more than 60% during the period versus a year ago.
Target continues to invest in products, stores and technology. The company saw the strongest growth in toys, baby products and seasonal gift items during the holiday period. Target has also been taking measures to improve its delivery service, and the acquisition of Shipt has benefited the company in this area. However, these investments have resulted in higher costs, which are likely to hurt margins.
Target has guided for comparable sales growth of around 5% for the fourth quarter. For the full year of 2018, the company expects GAAP EPS to be $5.41 to $5.61 and adjusted EPS to be $5.30 to $5.50.
In the third quarter, Target reported better-than-expected revenues but missed earnings estimates, which hurt the stock at the time. Revenue grew over 5% to $17.8 billion while adjusted earnings rose 20% to $1.09.
Over the past three months, Target’s stock has gained over 2%. The majority of analysts have rated the stock as Hold while some have rated it a Strong Buy.
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated